An expert summarizes that the emerging concept of broad immune potentiation—exemplified by therapies like Terra-002—seeks to activate multiple immune pathways for a more durable antitumor response in ...

Jansen stresses that testosterone is not a cure-all and often requires adjunct evaluation and management of other conditions such as sleep apnea or thyroid disorders.

Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.

Preclinical data shared during the 4th Annual Targeted Radiopharmaceuticals Summit (TRP) in San Diego, California, showed that the targeted radiotherapy ATNM-400 achieved robust antitumor efficacy in ...

Panelists discuss how multiple pharmacologic and clinical factors influence androgen deprivation therapy selection, including mechanism of action, delivery method, patient preferences, cardiovascular ...

The first patient has been dosed in the phase 1/2 redePHine trial, evaluating the safety and preliminary efficacy of ABO-101 for PH1.

The 500 mg regimen of abiraterone acetate demonstrated comparable anti-tumor activity and a favorable safety profile compared with the standard 1000 mg dose.

On July 17, 2025, a panel of experts convened by the FDA voiced growing consensus that the boxed warning on menopausal hormone therapies, particularly low-dose vaginal estrogen, is an outdated or ...